Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Carisma Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
CARM
Nasdaq
8731
https://sesenbio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Carisma Therapeutics Inc
Carisma Therapeutics Announces Upcoming Presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
- Apr 24th, 2024 9:05 pm
Carisma Therapeutics to Present New Data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
- Apr 22nd, 2024 8:35 pm
Here's Why CARISMA THERAP (CARM) Is a Great 'Buy the Bottom' Stock Now
- Apr 4th, 2024 1:55 pm
Carisma Therapeutics to Present at Upcoming Conferences
- Apr 3rd, 2024 11:00 am
Carisma Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
- Apr 1st, 2024 12:35 pm
Carisma Therapeutics Announces Changes to its Board of Directors
- Apr 1st, 2024 11:00 am
Carisma Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting
- Mar 21st, 2024 9:00 pm
Carisma Therapeutics to Participate in TD Cowen's 44th Annual Health Care Conference
- Feb 28th, 2024 12:30 pm
Individual investors account for 30% of Carisma Therapeutics, Inc.'s (NASDAQ:CARM) ownership, while institutions account for 23%
- Feb 27th, 2024 10:11 am
Carisma Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Dec 21st, 2023 12:00 pm
First In Vivo CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration
- Dec 14th, 2023 12:00 pm
Here's Why We're A Bit Worried About Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Situation
- Dec 9th, 2023 12:21 pm
Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte
- Nov 28th, 2023 12:00 pm
Carisma Therapeutics to Participate in Evercore ISI HealthCONx Conference
- Nov 22nd, 2023 12:30 pm
Benign Growth For Carisma Therapeutics, Inc. (NASDAQ:CARM) Underpins Stock's 42% Plummet
- Nov 11th, 2023 12:07 pm
Carisma Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
- Nov 9th, 2023 12:30 pm
Carisma Presents Pre-Clinical Proof of Concept for in vivo CAR-M using mRNA platform in collaboration with Moderna at SITC
- Oct 31st, 2023 1:25 pm
Carisma to Present First Results From in vivo CAR-M Collaboration with Moderna at SITC 2023
- Oct 25th, 2023 1:11 pm
3 Top Under-$5 Stocks for Strong Gains and Positive Outlook
- Oct 12th, 2023 6:52 pm
Carisma Therapeutics to Present at Upcoming Investor Conferences
- Sep 5th, 2023 12:30 pm
Scroll